What Does a LI-RADS 5 Score Mean for Liver Lesions?

If your MRI report shows a LI-RADS 5 (or LR-5) lesion and you fall into a specific high-risk category (such as having cirrhosis, chronic Hepatitis B infection, or prior liver cancer), this means the lesion is very highly likely to be hepatocellular carcinoma (HCC) ^[1][2]. HCC is the most common primary liver cancer (cancer that starts in the liver).

Because this imaging score is so highly specific in this at-risk population, it is widely accepted as an imaging diagnosis of HCC, and you often do not need a liver biopsy ^[3].

What is LI-RADS?

LI-RADS stands for Liver Imaging Reporting and Data System. It is a standardized system created by medical professionals to guide how liver imaging (like CT scans and MRIs) is interpreted for adults at high risk of developing HCC ^[2].

The system categorizes liver observations on a scale from 1 to 5, along with a few special categories:

• LR-1 and LR-2: Definitely or probably non-cancerous (benign).
• LR-3: Intermediate probability of HCC.
• LR-4: Probably HCC.
• LR-5: Definitely HCC (very high probability of HCC in the target population) ^[1].
• LR-M: Probably or definitely malignant, but not specific to HCC (could be another type of cancer) ^[4].
• LR-TIV: Tumor in a vein.

The Major Features of an LR-5 Score

For a lesion to be categorized as LR-5, the radiologist must see a specific combination of major imaging features on your scan ^[5]. Not every LR-5 lesion will have all of these features; the required combination depends on the size of the lesion and the specific version of LI-RADS being used.

Examples of major features include:

• Nonrim arterial phase hyperenhancement (APHE): The tumor enhances (lights up) more than the surrounding liver tissue during the early phase after intravenous contrast dye is given ^[5]. This happens because HCC tumors develop their own extra blood vessels.
• Nonperipheral washout: In the later phases of the scan, the lesion appears darker (hypoenhancing) compared to the surrounding liver tissue ^[5].
• Enhancing capsule: A smooth, distinct border that lights up around the edge of the tumor (distinct from a generic or irregular rim, which might point toward other conditions).
• Threshold growth: The tumor has grown by a specific, significant amount in a short time between scans ^[6].

Why a Biopsy May Not Be Needed

In many other cancers, a biopsy (using a needle to remove a tissue sample) is strictly required to confirm a diagnosis. However, liver biopsies carry small risks, such as bleeding or a rare chance of spreading cancer cells.

When you are in the validated high-risk population (e.g., cirrhosis or chronic Hepatitis B) ^[2], the combination of features like nonrim APHE and washout is highly specific to HCC. Because the probability of HCC is so high (often ~95% or greater), guidelines accept an LR-5 score as an official diagnosis without tissue confirmation ^[1][3].

When Might a Biopsy Still Be Needed?

While an LR-5 score often avoids a biopsy, it is not a 100% guarantee, and tissue confirmation may still be recommended if:

• You are not in the high-risk population: If you do not have cirrhosis, chronic Hepatitis B, or a history of HCC, the LR-5 criteria are not considered definitive on their own, and a biopsy may be needed to rule out other conditions ^[2].
• There are atypical features: If the MRI shows an LR-M categorization, it means the lesion is malignant but doesn’t perfectly match typical HCC, so your doctor may need a biopsy to see if it is a different type of liver cancer ^[7].
• Clinical trials or specific treatments: Occasionally, tissue confirmation is required to enter a clinical trial or to qualify for certain systemic therapies ^[3].

What Happens Next?

It is important to understand that an LR-5 score is an imaging diagnosis, not a cancer stage. The MRI alone does not dictate your treatment ^[3]. Your next steps will typically involve a multidisciplinary liver care team reviewing your case. They will look at the number and size of your lesions, whether the cancer has spread, your overall liver function (including tests for portal hypertension and blood tests like AFP), and your general health to recommend the best treatment plan for you.